| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.5M | -30.3% | -41.8% |
| SG&A Expense | $4.3M | -14.4% | -27.7% |
| Operating Income | -$13.8M | +26.1% | -22.4% |
| Net Income | -$15.8M | +15.7% | -49.0% |
| EPS (Basic) | -$0.27 | +15.6% | -22.7% |
| EPS (Diluted) | -$0.27 | +15.6% | -22.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.3M | -54.3% | -85.3% |
| Current Assets | $9.7M | -53.1% | -84.0% |
| Total Assets | $15.9M | -41.4% | -74.4% |
| Current Liabilities | $18.0M | +8.3% | -7.6% |
| Total Liabilities | $47.1M | +7.5% | +20.1% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$40.3M | — | — |
| Financing Cash Flow | -$437K | — | — |
| -$31.2M |
| -86.5% |
| -236.0% |